Outcome and Follow-up
Atorvastatin and verapamil were ceased from hospital presentation.
Prednisolone 30 mg once daily was commenced and she was discharged with
a plan to reduce dosage by 5 mg every five days. Upon follow-up one week
later, there was marked improvement of the purpuric rash with no
residual scarring or pigmentation. On one month follow-up, the rash had
resolved and there was no evidence of end-organ or systemic vasculitis
manifestations.